Valved holding chambers are widely prescribed to assist patients receiving inhaled medications by avoiding losses caused by imperfect coordination of inhalation and actuation and also to reduce oropharyngeal deposition.
Regardless of whether using a solution based formulation (like Qvar) or a suspension formulation (Flovent), the use of a valved holding chamber reduced the amount of medication deposited in the mouth (oropharynx) and increased the potential for lung delivery
This study can be used to help demonstrate the value of using a valved holding chamber for both solution and suspension formulated metered dose inhalers and for all patient populations, including adults
Do you use a puffer to manage your asthma or other respiratory condition? If so, you may have heard about using a spacer with your puffer. But what is a spacer and how does it work? This article explores the benefits of using a spacer with your puffer and provides tips on how to use one properly. Whether you're new to using a spacer or just looking to improve your technique, this article has you covered.
Do you use a puffer to manage your asthma or other respiratory condition? If so, you may have heard about using a spacer with your puffer. But what is a spacer and how does it work? This article explores the benefits of using a spacer with your puffer and provides tips on how to use one properly. Whether you're new to using a spacer or just looking to improve your technique, this article has you covered.
The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
The influence of inhalation flow profile was significant for one of the DPIs.
More consistent dose delivery was achieved with the breath actuated technology rather than breath enhanced. Delivering medication only when the patient inhales would result in more stable therapy if I:E ratio was to change with disease< progression or if the patient took breaks to talk during treatment.
As current MDIs contain hydrofluorocarbon propellants, it would be beneficial to find ways to reduce carbon emissions without compromising patient safety.
This lab study investigated a way to optimize the modelled lung dose per actuation while at the same time minimizing the carbon emissions from the MDI
Evaluations of inhaler use have demonstrated that mishandling of MDIs is commonplace.
One of the most common errors is the failure to coordinate inhalation with actuation of the inhaler
One of the reasons why VHCs are often prescribed, is to reduce the severity of this error
This Functional Respiratory Imaging (FRI) based study assessed the likely severity of a short inhalation delay (from actuation) with an MDI alone and how it contrasted to the use with a VHC
Inhaled tobramycin is recommended for use in cystic fibrosis patients for treatment of Pseudomonas aeruginosa infection. This in vitro study looked at antibiotic delivery using a BA nebulizer/compressor system and two BE nebulizer/compressor systems.
